ReviewCurrent drug targets2010
Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?
Review in Current drug targets, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- An allosteric inhibitor of RhoGAP class-IX myosins suppresses the metastatic features of cancer cells.Nature communications · 2024Article
- A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.Breast cancer research : BCR · 2023Article
- Rho GTPases: Big Players in Breast Cancer Initiation, Metastasis and Therapeutic Responses.Cells · 2020Review
- Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasionOncotarget · 2018Article
- Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.British journal of cancer · 2017Article
- Involvement of Rho GAP GRAF1 in maintenance of epithelial phenotype.Cell adhesion & migration · 2017Article
- Rho GTPases: Anti- or pro-neoplastic targets?Oncogene · 2017Review
- Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion.PloS one · 2014Article
- The SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth and RhoA signaling in breast cancer.Molecular cancer research : MCR · 2014Article
- P190B RhoGAP overexpression in the developing mammary epithelium induces TGFβ-dependent fibroblast activation.PloS one · 2013Article
- Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.PloS one · 2013Article
- Deleted in Colorectal Cancer (DCC) pathfinding: axon guidance gene finally turned tumor suppressor.Current drug targets · 2012Article
- Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).International journal of oncology · 2012Review
- Article
- The Rho GTPase Cdc42 is required for primary mammary epithelial cell morphogenesis in vitro.Small GTPases · 2011Article
- P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.Breast cancer research : BCR · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Rho GTPase signaling is altered in human breast tumors, and elevated expression and activation of Rho GTPases correlate with tumor progression, metastasis, and poor prognosis. Here we review the evidence that Rho signaling functions as a key regulator of cell cycle, mitosis, apoptosis, and invasion during breast cancer growth and progression and discuss whether these pleiotropic actions enhance or limit the targetability of this network. We propose that depending on the stage and subtype of breast cancer, targeting Rho signaling may have chemopreventative, anti-tumor, and anti-metastatic efficacy. An understanding of how Rho signaling is perturbed in specific stages and subtypes of breast cancer and how it functions in the context of the complex in vivo environment during the stochastic process of tumor formation and progression are necessary in order to effectively target this signaling network for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.